Topical 15% Resorcinol Is Associated with High Treatment Satisfaction in Patients with Mild to Moderate Hidradenitis Suppurativa

• Published in: Dermatology (Basel) Vol. 238; no. 1; p. 82
• Main Authors: Docampo-Simón, Alexandre, Beltrá-Picó, Iván, Sánchez-Pujol, María José, Fuster-Ruiz-de-Apodaca, Rosa, Selva-Otaolaurruchi, Juan, Betlloch, Isabel, Pascual, José Carlos
• Format: Journal Article
• Language: English
• Published: Switzerland 2022
• Subjects: Administration, Topical; Adult; Cross-Sectional Studies; Female; Hidradenitis Suppurativa - drug therapy; Humans; Male; Patient Satisfaction - statistics & numerical data; Resorcinols - administration & dosage; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Topical treatment; Patient satisfaction; Hidradenitis suppurativa; Treatment Satisfaction Questionnaire for Medication; Resorcinol
• ISSN: 1421-9832
• DOI: 10.1159/000515450

Topical 15% resorcinol is commonly used in clinical practice for the treatment of nodules and abscesses in patients with hidradenitis suppurativa (HS). It has been shown to be clinically effective in some small studies, but data on satisfaction perceived by patients are lacking. The Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 is a validated measure of patient satisfaction, evaluating four domains: effectiveness, side effects, convenience, and global satisfaction. Our objective was to obtain data from HS patients regarding resorcinol treatment satisfaction and its relationship with clinical and epidemiological variables. We performed a cross-sectional study providing TSQM version 1.4 questionnaires to HS patients who had been prescribed topical resorcinol during the previous 24 months. Ninety-two patients answered the questionnaire. Eighty-five out of 92 (92.4%) were Hurley II and 7 Hurley I. The mean total score was 317.5 out of 400 (71.0 points in effectiveness, 93.6 in side effects, 79.3 in convenience, and 73.2 in global satisfaction). Total score was higher in men than in women (329.7 vs. 311.6, p = 0.026) and higher scores on convenience were seen in patients who were not overweight or obese (86.9 vs. 77.1, p = 0.016). Most patients (65, 70.6%) denied having any side effect. 78 (84.8%) of the patients would recommend the treatment. The results of this study suggest that HS patients treated with resorcinol 15% are very satisfied with this treatment.